These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2813805)

  • 1. Long term treatment with oxaprotiline in patients with major depression.
    Katz RJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):875-83. PubMed ID: 2813805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaprotiline in the treatment of endogenous depressed inpatients an early clinical trial.
    Schmauss M; Laakmann G; Dieterle D; Blaschke D
    Pharmacopsychiatry; 1985 Jul; 18(4):282-5. PubMed ID: 3895255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind study of oxaprotiline versus clomipramine in the treatment of depressive inpatients.
    Wolfersdorf M; Binz U; Wendt G; Metzger R; Hole G
    Neuropsychobiology; 1987; 17(1-2):41-8. PubMed ID: 3306439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CGP 12.103 A versus clomipramine in the treatment of depressed inpatients--results of a double-blind study.
    Wolfersdorf M; Wendt G; Binz U; Steiner B; Hole G
    Pharmacopsychiatry; 1988 Jul; 21(4):203-7. PubMed ID: 3060885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The Eppendorf Mood and Motivation Scale as assessment procedure in the clinical evaluation of an antidepressive agent].
    Binz U; Wendt G
    Fortschr Med; 1982 Dec; 100(45):2111-7. PubMed ID: 6757074
    [No Abstract]   [Full Text] [Related]  

  • 6. Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: a double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives.
    Emrich HM; Berger M; Riemann D; von Zerssen D
    Pharmacopsychiatry; 1987 Mar; 20(2):60-3. PubMed ID: 3108909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Further clinical experiences with maprotiline in endogeneous depressions].
    Náhunek K; Svestka J; Rysánek R; Cesková E
    Act Nerv Super (Praha); 1982 May; 24(2):81-7. PubMed ID: 7048835
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative study of levoprotiline and amitriptyline in endogenous depressions.
    Faltus F; Molcan J; Svestka J; Náhunek K; Mrna B; Zapletálek M; Krekule P; Janecková E; Koníková M; Pazdírek S
    Act Nerv Super (Praha); 1989 Dec; 31(4):279-80. PubMed ID: 2638109
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential effects of the enantiomers R(-) and S(+) oxaprotiline on major endogenous depression, the sleep EEG and neuroendocrine secretion: studies on depressed patients and normal controls.
    Steiger A; Gerken A; Benkert O; Holsboer F
    Eur Neuropsychopharmacol; 1993 Jun; 3(2):117-26. PubMed ID: 8364347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Psychometric findings in treatment using the selective MAO-A inhibitors moclobemide and maprotiline].
    Classen W
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():41-3. PubMed ID: 2587675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic superiority of maprotiline versus doxepin in geriatric depression.
    Gwirtsman HE; Ahles S; Halaris A; DeMet E; Hill MA
    J Clin Psychiatry; 1983 Dec; 44(12):449-53. PubMed ID: 6361005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maprotiline in affective illness. Plasma concentration and clinical response.
    Norman TR; Burrows GD; Maguire KP; McIntyre IM; Scoggins BA
    J Affect Disord; 1983 May; 5(2):147-54. PubMed ID: 6222094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amitriptyline and oxaprotiline in the treatment of hospitalized depressive patients. Clinical aspects, psychophysiology, and drug plasma levels.
    Giedke H; Gaertner H; Breyer-Pfaff U; Rein W; Axmann D
    Eur Arch Psychiatry Neurol Sci; 1986; 235(6):329-38. PubMed ID: 3527706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine 40 mg vs maprotiline 75 mg in the treatment of out-patients with depressive disorders.
    Poelinger W; Haber H
    Int Clin Psychopharmacol; 1989 Jan; 4 Suppl 1():47-50. PubMed ID: 2644340
    [No Abstract]   [Full Text] [Related]  

  • 15. Maprotiline (Ludiomil, Ciba 34,276-BA) and imipramine in depressed outpatients: a double-blind clinical study.
    Singh AN; Saxena B; Gent M; Nelson HL
    Curr Ther Res Clin Exp; 1976 Apr; 19(4):451-62. PubMed ID: 816603
    [No Abstract]   [Full Text] [Related]  

  • 16. [The effect of maprotiline on target symptoms of depressive states].
    Faltus F
    Act Nerv Super (Praha); 1982 May; 24(2):99-100. PubMed ID: 7102230
    [No Abstract]   [Full Text] [Related]  

  • 17. Zimelidine vs maprotiline in depressed outpatients. A preliminary report.
    d'Elia G; Hällström T; Nyström C; Ottosson JO
    Acta Psychiatr Scand Suppl; 1981; 290():225-35. PubMed ID: 6452793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with maprotiline.
    Kabes J; Dostal T; Roth Z
    Act Nerv Super (Praha); 1982 May; 24(2):93-8. PubMed ID: 7048837
    [No Abstract]   [Full Text] [Related]  

  • 19. [Changes in slow evoked potentials in depressed patients treated with amitriptyline and oxaprotiline].
    Giedke H; Heimann H; Rein W
    Rev Electroencephalogr Neurophysiol Clin; 1987 Sep; 17(3):279-87. PubMed ID: 3685573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressant plasma levels and clinical response in depressed patients treated with oxaprotiline and doxepin.
    Hrdina PD; Lapierre YD; Horn E; Bakish D; Browne M
    Int Clin Psychopharmacol; 1988 Jul; 3(3):205-14. PubMed ID: 3153709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.